---
title: "Monopar says FDA grants rare pediatric disease designation for ALXN1840 in Wilson disease"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291279018.md"
description: "Monopar Therapeutics received FDA Rare Pediatric Disease designation for ALXN1840 to treat Wilson disease. This designation positions the drug for a potential pediatric Priority Review Voucher upon NDA approval, which can be sold or used."
datetime: "2026-06-30T12:02:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291279018.md)
  - [en](https://longbridge.com/en/news/291279018.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291279018.md)
generator: "portal-rs"
---

# Monopar says FDA grants rare pediatric disease designation for ALXN1840 in Wilson disease

-   Monopar Therapeutics received FDA Rare Pediatric Disease designation for ALXN1840 to treat Wilson disease. \* The designation positions ALXN1840 for a potential pediatric Priority Review Voucher on NDA approval, which can be sold or used. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monopar Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-022086), on June 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [MNPR.US](https://longbridge.com/en/quote/MNPR.US.md)

## Related News & Research

- [Monopar starts rolling FDA NDA submission for ALXN1840 in Wilson disease](https://longbridge.com/en/news/293470001.md)
- [Monopar Therapeutics director Raymond Anderson sells USD 349,125 of common shares](https://longbridge.com/en/news/297238555.md)
- [Ionis: FDA approves ZANVASTRO for Alexander disease, pivotal study shows 33.3% gait stabilization](https://longbridge.com/en/news/298024012.md)
- [Trump is waging a war on America's children — and he's winning](https://longbridge.com/en/news/298133228.md)
- [Zenas Biopharma outlines autoimmune disease pipeline in corporate presentation](https://longbridge.com/en/news/297813603.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**